IJCM  Vol.12 No.1 , January 2021
Well Controlled Blood Pressure in Turkish Patients: How Many Drugs Are Required to Attain and Maintain the Blood Pressure Goal?
Abstract: Background: This study aimed to determine the number of antihypertensive agents required to achieve optimal blood pressure (BP) in Turkish hypertensive patients. Material and Methods: Totally 400 hypertensive patients (114 males and 286 females) were enrolled. BP was measured by patients at home twice a day. The patients were called for controlling in every four weeks, and those who had BP < 140/90 were not followed-up. In patients with BP > 140/90 drug, doses were increased or another antihypertensive drug added and the patients were continued to be followed-up. Results: In the first follow-up (on the 4th week), 152 (38%) patients, including 35 (31%) men and 117 (41%) women, attained the goal BP. The mean duration of hypertension in single, double, triple, and quadruple treatment groups was 6.2 ± 5.0, 6.8 ± 5.9, 8.8 ± 5.4, and 10.4 ± 6.6 years, respectively. In the beginning, the median number of agents used for each patient was 2.17. When the follow-up was concluded, the median of agents used for each patient was 2.72. Conclusion: Thirty-eight percent of participants had controlled hypertension in the first follow-up. Women had better BP control. The median number of agents required for attaining and maintaining BP goal was 2.72. More drugs are needed when hypertension gets longer.
Cite this paper: Temizel, M. , Calap, U. , Cit, M. , Azermir, M. and Arman, Y. (2021) Well Controlled Blood Pressure in Turkish Patients: How Many Drugs Are Required to Attain and Maintain the Blood Pressure Goal?. International Journal of Clinical Medicine, 12, 23-33. doi: 10.4236/ijcm.2021.121004.

[1]   Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K. and He, J. (2005) Global Burden of Hypertension: Analysis of Worldwide Data. Lancet, 365, 217-223.

[2]   Marma, A.K. and Lloyd-Jones, D.M. (2009) Systematic Examination of the Updated Framingham Heart Study General Cardiovascular Risk Profile. Circulation, 120, 384-390.

[3]   Chobanian, A.V. (2009) The Hypertension Paradox—More Uncontrolled Disease Despite Improved Therapy. New England Journal of Medicine, 361, 878-887.

[4]   Lloyd-Jones, D.M., Evans, J.C. and Levy, D. (2005) Hypertension in Adults across the Age Spectrum: Current Outcomes and Control in the Community. JAMA, 294, 466-472.

[5]   Lewington, S., Clarke, R., Qizilbash, N., Peto, R. and Collins, R. (2002) Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality: A Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies. Lancet, 360, 1903-1913.

[6]   Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., et al. (2013) ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 34, 2159-2219.

[7]   James, P.A., Oparil, S., Carter, B.L., et al. (2014) Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311, 507-520.

[8]   American Diabetes Association (2013) Standards of Medical Care in Diabetes—2013. Diabetes Care, 36, S11-S66.

[9]   KDIGO (2012) Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International Supplements, 2, 341-342.

[10]   Mancia, G. and Grassi, G. (2020) Systolic and Diastolic Blood Pressure Control in Antihypertensive Trials. Journal of Hypertension, 20, 1461-1464.

[11]   Wolf-Maier, K., Cooper, R.S., Kramer, H., Banegas, J.R., Giampaoli, S., Joffres, M.R., et al. (2004) Hypertension Treatment and Control in Five European Countries, Canada, and the United States. Hypertension, 43, 10-17.

[12]   Ong, K.I., Cheung, B.M., Man, Y.B., Lau, C.P. and Lam, K.S.L. (2007) Prevalence, Awareness, Treatment, and Control of Hipertension among United States Adults 1999-2004. Hypertension, 49, 69-75.

[13]   Erdine, S. and Aran, S.N. (2004) Current Status of Hypertension Control around the World. Clinical and Experimental Hypertension, 26, 731-738.

[14]   Kearney, P., Whelton, M., Reynolds, K., Whelton, P.K. and He, J. (2004) Worldwide Prevalence of Hypertension: A Systematic Review. Journal of Hypertension, 22, 11-19.

[15]   Hajjar, I. and Kotchen, T.A. (2003) Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000. JAMA, 290, 199-206.

[16]   Peralta, C.A., Hicks, L.S., Chertow, G.M., Ayanian, J.Z., Vittinghoff, E., Lin, F., et al. (2005) Control of Hypertension in Adults with Chronic Kidney Disease in the United States. Hypertension, 45, 1119-1124.

[17]   Burt, V.L., Whelton, P., Roccella, E.J., Brown, C., Cutler, J.A., Higgins, M., et al. (1995) Prevalence of Hypertension in the US Adult Population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension, 25, 305-313.

[18]   Ong, K.L., Tso, A.W., Lam, K.S. and Cheung, B.M. (2008) Gender Difference in Blood Pressure Control and Cardiovascular Risk Factors in Americans with Diagnosed Hypertension. Hypertension, 51, 1142-1148.

[19]   Macedo, M.E., Lima, M.J., Silva, A.O., Alcantara, P., Ramalhinho, V. and Carmona, J. (2005) Prevalence, Awareness, Treatment and Control of Hypertension in Portugal: The PAP Study. Journal of Hypertension, 23, 1661-1666.

[20]   Meisinger, C., Heier, M., Völzke, H., Löwel, H., Mitusch, R., Hense, H.-W., et al. (2006) Regional Disparities of Hypertension Prevalence and Management within Germany. Journal of Hypertension, 24, 293-299.

[21]   Wyatt, S.B., Akylbekova, E.L., Wofford, M.R., Coady, S.A., Walker, E.R., Andrew, M.E., et al. (2008) Prevalence, Awareness, Treatment, and Control of Hypertension in the Jackson Heart Study. Hypertension, 51, 650-656.

[22]   Pereira, M., Lunet, N., Azevedo, A. and Barros, H. (2009) Differences in Prevalence, Awareness, Treatment and Control of Hypertension between Developing and Developed Countries. Journal of Hypertension, 27, 963-975.

[23]   UK Prospective Diabetes Study Group (1998) Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. BMJ, 317, 703-713.

[24]   Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.-H., et al. (2001) Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with type 2 Diabetes and Nephropathy. New England Journal of Medicine, 345, 861-869.

[25]   Dahlöf, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M., et al. (2005) Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial. Lancet, 366, 895-906.

[26]   Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlöf, B., Elmfeldt, D., Julius, S., et al. (1998) Effects of intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients with Hypertension: Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial. HOT Study Group. Lancet, 351, 1755-1762.

[27]   Peterson, J.C., Adler, S., Burkart, J.M., Greene, T., Hebert, L.A., Hunsicker, L.G., et al. (1995) Blood Pressure Control, Proteinuria, and the Progression of Renal Disease: The Modification of Diet in Renal Disease Study. Annals of Internal Medicine, 123, 754-762.

[28]   Calhoun, D.A., Lacourciere, Y., Chiang, Y.T. and Glazer, R.D. (2009) Triple Antihypertensive Therapy with Amlodipine, Valsartan, and Hydrochlorothiazide: A Randomized Clinical Trial. Hypertension, 54, 32-39.

[29]   National Collaborating Centre for Chronic Conditions (2006) Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update. London: Royal College of Physicians.

[30]   Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M.J., et al. (2009) Reappraisal of European Guidelines on Hypertension Management: A European Society of Hypertension Task Force Document. Journal of Hypertension, 27, 2121-2158.

[31]   Julius, S., Kjeldsen, S.E., Brunner, H., et al. (2003) VALUE Trial: Long-Term Blood Pressure Trends in 13,449 Patients with Hypertension and High Cardiovascular Risk. American Journal of Hypertension, 16, 544-548.

[32]   Nesbitt, S.D. (2007) Antihypertensive Combination Therapy: Optimizing Blood Pressure Control and Cardiovascular Risk Reduction. The Journal of Clinical Hypertension, 9, 26-32.

[33]   Sica, D.A. (2002) Rationale for Fixed-Dose Combinations in the Treatment of Hypertension: The Cycle Repeats. Drugs, 62, 443-462.

[34]   Chapman, N., Dobson, J., Wilson, S., et al. (2007) Effect of Spironolactone on Blood Pressure in Subjects with Resistant Hypertension. Hypertension, 49, 839-845.

[35]   Primenta, E. and Calhoun, DA. (2010) Treatment of Resistant Hypertension. Journal of Hypertension, 28, 2194-2195.